A5087863394- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
- Atherosclerosis and Cardiovascular Diseases
- Colorectal Cancer Treatments and Studies
- Single-cell and spatial transcriptomics
- T-cell and B-cell Immunology
- RNA modifications and cancer
- Cancer Immunotherapy and Biomarkers
- Atomic and Subatomic Physics Research
- Advanced Frequency and Time Standards
- Hepatocellular Carcinoma Treatment and Prognosis
First Affiliated Hospital of Anhui Medical University
2024-2025
Anhui Medical University
2024-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2025
Nanjing Drum Tower Hospital
2025
Sorbonne Université
2012
Observatoire de Paris
2012
Systèmes de Référence Temps-Espace
2012
Centre National de la Recherche Scientifique
2012
Abstract Hepatocellular carcinoma (HCC) stands as the fifth most prevalent malignant tumor on a global scale and presents second leading cause of cancer-related mortality. DNA damage-based radiotherapy (RT) plays pivotal role in treatment HCC. Nevertheless, radioresistance remains primary factor contributing to failure radiation therapy HCC patients. In this study, we investigated functional transketolase (TKT) repair double-strand breaks (DSBs) Our research unveiled that TKT is involved DSB...
ABSTRACT Targeting base excision repair (BER) has been an attractive strategy in cancer therapeutics. RNA‐binding motif protein 39 (RBM39) modulates the alternative splicing of numerous genes involved occurrence and progression. However, whether how RBM39 regulates BER hepatocellular carcinoma (HCC) remain unclear. Here, we found that under oxidative stress, degradation or knockdown decreased efficiency HCC cells using a well‐designed reporter. Further assays showed promoted cell...
We summarize the status of our development a Hg optical lattice clock.